Aerpio Therapeutics
9987 Carver Road
Suite 420
Cincinnati
Ohio
45242
United States
Tel: 513-985-1920
Fax: 513-985-0999
Website: http://www.aerpio.com/
About Aerpio Therapeutics
Aerpio Therapeutics is a new, clinical-stage biotechnology company focused on the development of novel small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Aerpio was created in a spin-out transaction from Akebia Therapeutics to enable more rapid development of its exciting compounds.Aerpio's two lead programs include a Tie-2 activator for diabetic macular edema (DME) and vascular leak, and a Hypoxia-inducible Factor 1-a (HIF1-a) stabilizer for wound healing and the treatment of inflammatory bowel disease. The lead compound for the Tie-2 program, AKB-9778, is currently completing its initial Phase 1 clinical trial, and the HIF1-a stabilization program is progressing toward the clinic with support, in part, from the United States Department of Defense and National Institutes of Health.
The Aerpio team is composed of highly experienced individuals from all facets of pharmaceutical development. During the last 4 years, this team has successfully sharpened their skills at Akebia Therapeutics in the fast paced world of venture backed biopharmaceuticals.
51 articles about Aerpio Therapeutics
-
Aerpio Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update
3/13/2018
TIME-2b Clinical Trial of AKB-9778 in patients with diabetic retinopathy remains on track
-
Aerpio Pharmaceuticals Announces Appointment of Michael Rogers as Chief Financial Officer
11/14/2017
Mr. Rogers has more than 25 years of experience in the biopharmaceutical industry, serving as Chief Financial Officer (CFO) of five publicly-traded healthcare companies.
-
Aerpio Reports Third Quarter 2017 Financial Results
11/13/2017
As of September 30, 2017, cash and cash equivalents totaled $24.8 million.
-
Aerpio Announces Appointment Of Stephen Hoffman, M.D., Ph.D., As Chief Executive Officer And To The Board Of Directors And The Transition Of Joseph H. Gardner, Ph.D., To President And Founder
10/10/2017
-
Aerpio Reports Second Quarter 2017 Financial Results
8/14/2017
-
Aerpio Commences Trading On The OTCQB Market
8/9/2017
-
Aerpio Commences Trading On The OTCQB Market
8/8/2017
-
Aerpio Announces Initiation Of Patient Dosing In The TIME-2b Study, A Phase IIb Clinical Trial Of Lead Candidate AKB-9778 In Patients With Diabetic Retinopathy
6/29/2017
-
Aerpio Reports First Quarter 2017 Financial Results
5/16/2017
-
Akebia Spinoff Aerpio Scores $40 Million
3/16/2017
-
Aerpio Raises $40 Million
3/16/2017
-
Aerpio Initiates Phase Ia Study Of AKB-4924, A First In Class Once-Daily, Orally Administered HIF-1 Stabilizer, In Development To Treat Inflammatory Bowel Disease (IBD)
9/26/2016
-
Aerpio Reports Peer-Reviewed Publication Of Positive Clinical Results From The Phase IIa Study Of Lead Candidate, AKB-9778, In Diabetic Macular Edema (DME): The TIME-2 Trial
6/13/2016
-
Aerpio Announces Presentation Of Positive Results Of AKB-9778 In Patients With Diabetic Retinopathy From TIME-2 Phase IIa Study
2/10/2016
-
Aerpio Reports Positive Clinical Results From The Phase IIa Study Of Lead Candidate, AKB-9778, In Diabetic Macular Edema (DME): The TIME-2 Trial
11/17/2015
-
Aerpio Appoints Steve Pakola, M.D. As Chief Medical Officer
10/6/2015
-
Aerpio Announces Positive Results Of A Phase IIa Study Of AKB-9778 In Diabetic Macular Edema: The TIME-2 Trial
7/15/2015
-
Aerpio To Present At The 14th Annual Needham Healthcare Conference
4/9/2015
-
Aerpio Announces Publication Of Positive Results Of Phase 1b/2a Clinical Trial Of Novel Tie2 Activator, AKB-9778, For The Treatment Of Patients With Diabetic Macular Edema (DME) – TIME-1 Study
3/4/2015
-
Aerpio Completes Enrollment Of Phase 2 Study Of Tie2 Activator AKB-9778 For The Treatment Of Patients With Diabetic Macular Edema
12/4/2014